William Blair Issues Negative Estimate for Zoetis Earnings

Zoetis Inc. (NYSE:ZTS) – Investment analysts at William Blair reduced their Q1 2025 earnings per share (EPS) estimates for Zoetis in a note issued to investors on Friday, January 31st. William Blair analyst B. Vazquez now forecasts that the company will earn $1.38 per share for the quarter, down from their previous forecast of $1.45. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. William Blair also issued estimates for Zoetis’ Q2 2025 earnings at $1.63 EPS, Q3 2025 earnings at $1.66 EPS, Q4 2025 earnings at $1.52 EPS, FY2025 earnings at $6.20 EPS, Q1 2026 earnings at $1.54 EPS, Q2 2026 earnings at $1.82 EPS, Q3 2026 earnings at $1.86 EPS, Q4 2026 earnings at $1.70 EPS and FY2026 earnings at $6.92 EPS.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the firm posted $1.36 earnings per share. The company’s quarterly revenue was up 11.6% compared to the same quarter last year.

ZTS has been the topic of a number of other reports. Stifel Nicolaus lowered their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Morgan Stanley cut their target price on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. UBS Group began coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $215.00.

Zoetis Stock Down 1.1 %

ZTS stock opened at $170.81 on Monday. The stock has a 50-day simple moving average of $169.62 and a two-hundred day simple moving average of $179.46. Zoetis has a twelve month low of $144.80 and a twelve month high of $200.53. The firm has a market capitalization of $77.06 billion, a PE ratio of 32.11, a PEG ratio of 2.70 and a beta of 0.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Institutional Trading of Zoetis

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of Jackson Hole Trust bought a new position in shares of Zoetis in the fourth quarter worth about $641,000. Callahan Advisors LLC raised its stake in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after acquiring an additional 6,221 shares during the period. Kentucky Retirement Systems Insurance Trust Fund lifted its holdings in Zoetis by 32.0% during the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 17,707 shares of the company’s stock valued at $2,885,000 after purchasing an additional 4,293 shares in the last quarter. BKM Wealth Management LLC boosted its position in shares of Zoetis by 7.5% in the fourth quarter. BKM Wealth Management LLC now owns 8,393 shares of the company’s stock worth $1,367,000 after purchasing an additional 584 shares during the period. Finally, Kestra Investment Management LLC increased its stake in shares of Zoetis by 106.9% in the fourth quarter. Kestra Investment Management LLC now owns 6,057 shares of the company’s stock worth $987,000 after purchasing an additional 3,129 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. The ex-dividend date is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.